Clinical Trials for Mesothelioma Patients—Vaccine Therapy and GM-CSF: Disease Characteristics Criteria

Read about the concurrent therapy for a current clinical trial to test vaccine therapy GM-CSF on patients with the disease mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

Disease Characteristics Criteria:

· Cytologically or histologically confirmed diagnosis of 1 of the following:

o Acute myeloid leukemia, meeting the following criteria:

Documented Wilms tumor-1 (WT-1)-positive disease demonstrated by WT-1 protein on a pretreatment bone marrow biopsy OR detectable disease with real-time quantitative reverse transcriptase-polymerase chain reaction (RQ-PCR)
Completed induction chemotherapy, achieved clinical remission, and completed postremission therapy OR achieved clinical remission and have no plans for further postremission chemotherapy (= 65 years of age)

o Myelodysplastic syndromes, meeting the following criteria:

Documented WT-1-positive disease demonstrated by WT-1 protein on a pretreatment bone marrow biopsy OR detectable disease by RQ-PCR
International Prognostic Scoring System (IPSS) score of = Int-2
Not a candidate for cytotoxic chemotherapy

o Non-small cell lung cancer, meeting the following criteria:

Positive tumor staining for WT-1 in > 10% of cells
Stage III or IV disease
Completed chemotherapy, surgery, and/or radiotherapy

o Mesothelioma, meeting the following criteria:

Positive tumor staining for WT-1 in > 10% of cells
Unresectable or relapsed disease
Chemo-naive or received 1 prior chemotherapy regimen

Courtesy of ClinicalTrials.gov, a service of the U.S. National Institutes of Health

If you or a loved one has been diagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.